Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence

Sciaccaluga, Carlotta; Ghionzoli, Nicolò; Mandoli, Giulia Elena; D’Ascenzi, Flavio; Focardi, Marta; Valente, Serafina; Cameli, Matteo

doi:10.3390/biom12020334

Open AccessReview

Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence

by

Carlotta Sciaccaluga

^*,†,

Nicolò Ghionzoli

^†,

Giulia Elena Mandoli

,

Flavio D’Ascenzi

,

Marta Focardi

,

Serafina Valente

and

Matteo Cameli

Department of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, Italy

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Biomolecules 2022, 12(2), 334; https://doi.org/10.3390/biom12020334

Submission received: 30 December 2021 / Revised: 10 February 2022 / Accepted: 16 February 2022 / Published: 19 February 2022

(This article belongs to the Special Issue Molecular Biomarkers In Cardiology 2021)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Left ventricular assist devices (LVADs) have been representing a cornerstone therapy for patients with end-stage heart failure during the last decades. However, their use induces several pathophysiological modifications which are partially responsible for the complications that typically characterize these patients, such as right ventricular failure, thromboembolic events, as well as bleedings. During the last years, biomarkers involved in the pathways of neurohormonal activation, myocardial injury, adverse remodeling, oxidative stress and systemic inflammation have raised attention. The search and analysis of potential biomarkers in LVAD patients could lead to the identification of a subset of patients with an increased risk of developing these adverse events. This could then promote a closer follow-up as well as therapeutic modifications. Furthermore, it might highlight some new therapeutic pharmacological targets that could lead to improved long-term survival. The aim of this review is to provide current evidence on the role of different biomarkers in patients with LVAD, in particular highlighting their possible implications in clinical practice.

Keywords: LVAD; biomarkers; neurohormonal activation; adverse remodeling; inflammation

Share and Cite

MDPI and ACS Style

Sciaccaluga, C.; Ghionzoli, N.; Mandoli, G.E.; D’Ascenzi, F.; Focardi, M.; Valente, S.; Cameli, M. Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence. Biomolecules 2022, 12, 334. https://doi.org/10.3390/biom12020334

AMA Style

Sciaccaluga C, Ghionzoli N, Mandoli GE, D’Ascenzi F, Focardi M, Valente S, Cameli M. Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence. Biomolecules. 2022; 12(2):334. https://doi.org/10.3390/biom12020334

Chicago/Turabian Style

Sciaccaluga, Carlotta, Nicolò Ghionzoli, Giulia Elena Mandoli, Flavio D’Ascenzi, Marta Focardi, Serafina Valente, and Matteo Cameli. 2022. "Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence" Biomolecules 12, no. 2: 334. https://doi.org/10.3390/biom12020334

APA Style

Sciaccaluga, C., Ghionzoli, N., Mandoli, G. E., D’Ascenzi, F., Focardi, M., Valente, S., & Cameli, M. (2022). Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence. Biomolecules, 12(2), 334. https://doi.org/10.3390/biom12020334

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Biomarkers in Patients with Left Ventricular Assist Device: An Insight on Current Evidence

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI